The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 08, 2011
Filed:
Apr. 17, 2003
Magnus Von Knebel-doeberitz, Heidelberg, DE;
Johannes Gebert, Heidelberg, DE;
Michael Linnebacher, Stennweiler, DE;
Stefan Woerner, Heidelberg, DE;
Ruediger Ridder, Schriesheim, DE;
Peer Bork, Heidelberg, DE;
Yan Ping Yuan, Heidelberg, DE;
Magnus Von Knebel-Doeberitz, Heidelberg, DE;
Johannes Gebert, Heidelberg, DE;
Michael Linnebacher, Stennweiler, DE;
Stefan Woerner, Heidelberg, DE;
Ruediger Ridder, Schriesheim, DE;
Peer Bork, Heidelberg, DE;
Yan Ping Yuan, Heidelberg, DE;
MTM Laboratories, AG, Heidelberg, DE;
Abstract
The present invention relates to compounds and methods useful for the detection and treatment of disorders associated with frameshift mutations in coding microsatellite regions. The compounds and methods are applicable in cancers, especially of DNA mismatch repair deficient (MMR) sporadic tumors and HNPCC associated tumors. The compounds disclosed in the invention are useful for detection of disorders and in therapy such as e.g. immuno-therapy. The diagnostic methods relate to diagnosis and prognostic assessment of disorders associated with frameshift polypeptides originating from frameshift mutations in coding microsatellite regions of genes based on the detection of immunological entities directed against said frameshift polypeptides in body fluids. With respect to the treatment of cancer, especially of DNA mismatch repair deficient (MMR) sporadic tumors and HNPCC associated tumors, the invention pertains to methods which use immuno therapy with combinatorial mixtures of tumor specific frameshift peptides to elicit a cytotoxic T-cell response specifically directed against tumor cells for use in prevention as well as in curative treatment of cancers and precancers.